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Abstract 
Objective: To investigate the relationship between early second trimester serum 
lipidomic variation and maternal glycemic traits at 28 weeks, and to identify 
predictive lipid biomarkers for Gestational Diabetes (GDM). 
Research Design and Methods: Prospective study of 817 pregnant women 
(Discovery cohort, n=200; Validation cohort, n=617) who provided an early second 
trimester serum sample, and underwent oral glucose tolerance testing (OGTT) at 28 
weeks. In the discovery cohort, lipids were measured using direct infusion mass 
spectrometry, and correlated with OGTT results. Variable Importance in Projection 
(VIP) scores were used to identify candidate lipid biomarkers. Candidate biomarkers 
were measured in the validation cohort using Liquid Chromatography- Mass 
Spectrometry, and tested for associations with OGTT results and GDM status.  
Results: Early second trimester lipidomic variation was associated with 1-hour post-
load glucose levels, but not with fasting plasma glucose. Of the 13 lipid species 
identified by VIP scores, 10 had nominally significant associations with post-load 
glucose levels. In the validation cohort, 5 of these 10 lipids had significant 
associations with post-load glucose levels independent of maternal age and BMI, i.e. 
TG(51:1), TG(48:1), PC(32:1), PCae(40:3) and PCae(40:4). All except the last were 
also associated with maternal GDM status. Together, these 4 lipid biomarkers had 
moderate ability to predict GDM (Area under curve (AUC)= 0.71±0.04, p=4.85x10-7), 
and improved the prediction of GDM by age and BMI alone from AUC 0.69 to AUC 
0.74. 
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Conclusions: Specific early second trimester lipid biomarkers can predict maternal 
GDM status independent of maternal age and BMI, potentially enhancing risk factor-
based screening. 
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Introduction 
Gestational diabetes (GDM) affects 9-26% of pregnancies (1). It is clinically 
important because it increases the risk of obstetric complications (e.g. pre-eclampsia 
and shoulder dystocia), as well as neonatal complications (e.g. hypoglycemia and 
hyperbilirubinemia). In the multi-center Hyperglycemia and Adverse Pregnancy 
Outcomes (HAPO) study, a continuous linear relationship was shown between 
maternal glucose levels at 24-32 weeks of gestation and the odds of several adverse 
pregnancy outcomes, even for glucose levels well within the normal range (2). This 
has provided impetus for the International Association of Diabetes and Pregnancy 
Study Groups (IADPSG) to recommend universal screening for GDM via the 75g 
Oral Glucose Tolerance Test (OGTT) between 24-28 weeks gestation (3).  
This recommendation by the IADPSG has not been uniformly adopted due to various 
concerns, including the implications on service provision, and the large number of 
normoglycemic women who will have undergo what can be an unpleasant and poorly 
tolerated test (4). Some countries, such as the United Kingdom (4) and Italy (5), 
perform risk factor-based screening, with only high-risk individuals receiving the 
diagnostic 75g oral glucose tolerance tests. Specified risk factors include obesity, 
previous macrosomic baby, previous gestational diabetes, family history of diabetes 
and minority ethnic family origin with high prevalence of diabetes. In the United 
States, the American Diabetes Association and American College of Obstetricians 
and Gynecologists continue to endorse a two-step approach with an initial universal 
non-fasted 50g Glucose Load Test at 24-28 weeks gestation (6).   
Another recognized limitation of screening for GDM at 24-28 weeks gestation is the 
delay in detecting cases of GDM that developed in the first or early second 
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trimesters. By the time of screening, significant increased fetal adiposity may have 
developed (4,7,8). Although performed in a high-risk ethnic minority population, 
Agarwal and colleagues showed that over 40% of GDM cases could be diagnosed 
by a 75g OGTT performed before 18 weeks gestation (9). These limitations of 
universal 24-28 week OGTT support the potential value of predictive early 
gestational biomarkers for GDM. Biomarkers that have been studied include fasting 
plasma glucose (9) and more recently maternal metabolites (10,11), plasma proteins 
(12) and miRNA (13) using high throughput technologies. Although these efforts 
have not yet informed clinical strategies, the results of metabolomic studies in 
particular have shed valuable insights on the pathophysiology of GDM (11,14). 
Variations in lipid profiles have yet to be comprehensively studied, even though 
changes in maternal lipid metabolism are well-described from the beginning of 
pregnancy (15). In early pregnancy, plasma lipids, including triglycerides, 
phospholipids and cholesterol decrease, before steadily increasing from week 8 
onwards (15). The rise in triglycerides is accompanied by an increase in VLDL, LDL 
and HDL levels (16). Changes in lipids during GDM have also been observed, with 
GDM women having higher serum triglyceride levels, but lower LDL levels, 
compared to normoglycemic pregnant women (17).  
Therefore, we hypothesized that lipidomic variation in early second trimester 
maternal serum samples could be associated with later glucose tolerance measured 
at 28 weeks. Confirmation of this hypothesis would enable identification of candidate 
lipid biomarkers that are predictive of GDM, so as to improve GDM screening and 
provide mechanistic insights into the pathophysiology of GDM. 
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Research Design and Methods 
Recruitment and sample collection 
The Cambridge Baby Growth Study (CBGS) is a prospective longitudinal study that 
has been described previously (18–20). Briefly, 2212 women in early pregnancy 
were recruited between 2001 and 2009 from ultrasound clinics at the Rosie Maternal 
Hospital, Cambridge, UK. Such dating scans are routinely offered to all pregnant 
women receiving antenatal care, and are performed at 8-14 weeks gestation. 
Shortly after recruitment, at 15.2 ± 0.07 weeks gestation, a non-fasting venous blood 
sample was collected if women consented. After clotting and within 2 hours of 
sample collection, these samples were centrifuged at 3,000G for 10 min and the 
serum separated and stored at -80 oC. They were maintained at -80 °C until analysis, 
with the exception of a single freeze-thaw cycle to prepare the necessary aliquots for 
lipid analysis. A total of 1260 serum samples were collected.  
All participants were also invited for a standard 75g OGTT, which was performed at 
28 weeks gestation after an overnight fast. A total of 1069 women underwent the 
OGTT. Plasma glucose levels were analyzed by the standard glucose oxidase 
method. 
Cohort selection 
For this study, we excluded OGTT participants who (i) were missing either fasting or 
1-hour (1h) post-load venous plasma glucose level measurements (n=10), (ii) 
subsequently gave birth to twins (n=17), or (iii) did not provide a early second 
trimester serum sample (n=219). A very small number of participants (n=6) were also 
excluded for various other reasons, e.g. inadequate remaining serum samples, no 
6 
 
paired DNA sample (for use in other studies). This yielded a total of 817 women, who 
were assigned to a Discovery Cohort of 200 women, and a Validation Cohort of 617 
women. Women in the discovery cohort were selected because they had data on 
other genetic or phenotypic traits, which other ongoing studies in our group were 
interested in correlating lipidomic variation with. 
There were two differences in clinical characteristics between the discovery and 
validation cohorts. First, 1h post-load glucose levels were 0.27mM higher in the 
validation cohort (Table 1). This result was of borderline significance on univariate 
testing (p=0.05), and non-significant when multiple testing was accounted for using 
the Benjamini-Hochberg method (p=0.175). Importantly, there was no significant 
difference in the proportion of cases with GDM in the two groups. Second, samples 
were taken in the validation cohort at a slightly later gestation, approximately 0.5 
weeks later. 
Ethical approval 
The study protocol was approved by the local research ethics committee, 
Addenbrooke's Hospital, Cambridge, UK. Written informed consent was obtained 
from all participants. 
Lipid biomarker analyses  
In the discovery cohort the lipids were profiled by direct infusion mass spectrometry 
as described previously (21,22). For biomarker validation, we used a Liquid 
Chromatography-Mass Spectrometry (LC-MS) method as described before (23).  
Statistical analysis 
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Partial least squares (PLS) regression and PLS- Discriminant analysis (PLS-DA) 
were used to identify associations between lipidomics variables and OGTT results in 
the discovery cohort. Fitted models were considered significant if the Q2, i.e. R2 of 
the model as estimated by cross-validation, was positive. The importance of 
individual lipid species was quantified via the Variable Importance in Projection (VIP) 
score, and used to identify candidate lipid biomarkers. The VIP score is a widely 
used method of variable selection. It takes into account the amount of Y-variance 
explained by the projection, and the loadings of each variable on this projection, 
while adjusting for the absolute magnitude of each X-variable. As such, 2 variables 
with identical contribution to the explanatory power of the model will have identical 
VIP scores, regardless of which component they have a large influence on, or their 
absolute magnitudes. 
Standard linear and logistic regression techniques were used to assess the 
association between candidate lipid biomarkers and maternal OGTT results or GDM 
status. GDM was defined based on fasting and 1h post-load glucose levels using 
IADPSG thresholds, i.e. ≥5.1 and 10.0mM respectively. 2h post-load data was 
unavailable for most women and was omitted from our case definition for uniformity. 
This is acceptable as only 7% of UK women with GDM are diagnosed based on the 
2h measurement alone (1).  
Logistic regression was used to combine the predictive ability of candidate lipid 
biomarkers, which was then assessed using Receiver Operating Characteristics 
(ROC) plots. Where backward stepwise selection was used, a significance threshold 
of 0.10 for removal was employed. Linear discriminant analysis was used to ensure 
the robustness of these results. 
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The threshold for statistical significance was 0.05. For the discovery cohort 
uncorrected p-values were considered, whereas in the validation cohort p-values 
were corrected for multiple testing using the Benjamini-Hochberg method. Values in 
the text are given as mean ± SE unless otherwise specified. Regression coefficients 
were standardized by the predictor, i.e. change in response variable for each 
standard deviation increase in the predictor. 
PLS and PLS-DA regression was performed using SIMCA version 14 (MKS Umetrics 
AB, Umeå, Sweden). All other analyses were performed using SPSS version 21 
(IBM, Armonk, NY, USA). 
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Results 
Association between early second trimester lipidomic variation and 28-week glucose 
tolerance 
Analysis of the discovery cohort was confined to 196 samples as 4 samples were 
found to be unsuitable for analysis due to hemolysis. In these samples, 189 lipid 
species were detected. 
A PLS model was constructed to examine the extent to which early second trimester 
lipidomic variation explained post-load venous glucose levels during a OGTT at 28 
weeks. The resulting model yielded 1 fitted component, which used 15% of lipidomic 
variation (R2X) to explain 11% (R2Y) of variation in post-load glucose levels. This 
was robust to internal cross-validation, yielding a Q2 of 4%. 
Because some lipid species may show non-linear relationships with post-load 
glucose levels, we divided participants into tertiles of OGTT levels, and constructed a 
PLS-DA model to explain membership in the top tertile. The resulting model also 
yielded a single component, which used 15% of lipidomic variation to explain 9% of 
the variation in top tertile membership, with a Q2 of 1.31%. 
Similar PLS and PLS-DA models were also constructed to explore the relationship 
between lipidomic variation and fasting plasma glucose levels. However, the models 
were overfitted, with the PLS and PLS-DA models yielding a Q2 of -3% (R2X=15%, 
R2Y=9%) and -10% (R2X=9%, R2Y=8%) respectively. These models were not used 
in subsequent analyses. 
Identification of lipid biomarkers of post-load plasma glucose levels 
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From each of the two models considering post-load glucose levels, approximately 10 
lipids with the highest VIP scores were selected, with the exact cut-point selected 
using a graphical method (Fig. 1a, b). The PLS model yielded 9 lipid species and the 
PLS-DA model 10 species, with 5 lipid species being identified in both models. One 
of the species annotated as DG-H2O(32:0) was likely to be an in-source fragment of 
a different lipid species. As in-source fragments are artifacts of mass spectrometry, 
this species was disregarded, leaving a total of 13 lipid species identified. 
The 13 lipid species were regressed against post-load glucose levels or membership 
in the top tertile thereof. To ensure that they were not simply surrogates for known 
risk factors of GDM, maternal age and pre-pregnancy BMI were adjusted for. This 
resulted in 10 of the 13 lipid species having a nominally significant association with 
post-load glucose levels and/or the top tertile thereof (Supplementary Table S1). The 
2 lipid species showing the strongest association with post-load glucose levels were 
the triglyceride TG(51:1) (0.40mM per SD increase, p=8.88E-4) and the choline ether 
phospholipid PCae(40:3) (-0.41mM per SD increase, p=9.73E-4) (Supplementary 
Table S2).  
Further examination of the correlations between these 10 lipid species revealed 
clustering into 2 large groups (Fig. 1c). The first group contained the choline ether 
phospholipids, whereas the second group contained triglycerides and a 
phosphatidylcholines. 
Validation of lipid biomarkers of post-load plasma glucose levels 
These 10 candidate lipid biomarkers were measured in the validation set of 617 
subjects using a LC-MS method. This provided additional chromatographic 
information, eliminating any possible artifacts introduced by the shotgun approach in 
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the discovery set. With this method we were unable to detect PCae(44:4) in our 
samples, suggesting that this putative signal in the discovery set was an artifact, and 
it was omitted from further analysis. We also omitted 20 samples in which none of 
the remaining 9 lipid species were detectable, as this was likely indicative of poor 
sample quality. This left data on the 9 candidate lipid biomarkers in 597 subjects for 
analysis. 
Of the 9 remaining lipid species, 5 showed significant associations with post-load 
glucose levels even after adjustment for maternal age and BMI and correction for 
multiple testing (Table 2). TG(51:1), TG(48:1) and PC(32:1) were positively 
associated with maternal post-load glucose levels, whereas PCae(40:3) and 
PCae(40:4) were inversely associated with maternal post-load glucose levels. 
Logistic regression against membership in the top tertile of post-load glucose levels 
did not validate any additional candidate lipid species, nor did adjusting for 
gestational age at the time of serum sample collection (data not shown). 
As fasting and post-load glucose levels have common pathophysiological 
determinants and were moderately correlated in our cohort (r=0.343, p<0.001), we 
tested the 9 putative lipid biomarkers for an association with fasting glucose levels 
(data not shown). TG(51:1) and PCae(40:4) showed significant associations with 
fasting glucose levels, even after adjusting for multiple testing. However, after 
adjusting for maternal age and BMI, only TG(51:1) remained significant (0.06mM per 
SD increase, p-value=0.003, Benjamini-Hochberg p-value=0.02). 
Lipid predictors of Gestational Diabetes 
Of the 597 subjects in the validation cohort, 53 met the criteria for GDM. The 5 
validated lipid species were tested for association with GDM. TG(51:1), TG(48:1), 
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PC(32:1), and PCae(40:4) were significantly associated with GDM, even after 
adjustment for maternal age and maternal BMI, and correction for multiple testing 
(Fig. 2a). While not reaching significance, PCae(40:3) nonetheless demonstrated a 
strong trend in the same direction as PCae(40:4) (Benjamini-Hochberg p-
value=0.07).  
To assess the combined predictive ability of these 4 lipid species, logistic regression 
was used to calculate the probability of GDM status of each subject, and the 
probability scores used to construct a ROC curve (Fig. 2b). This yielded an AUC of 
0.709 ± 0.040 (p=4.85E-7). Similar results were obtained using linear discriminant 
analysis.  
Of the 597 subjects, 410 (including 37 GDM cases) had available data on maternal 
age and BMI. This enabled us to assess the additional predictive power conferred by 
these 4 lipid biomarkers over maternal age and BMI alone. In this sub-group, 
maternal age and BMI produced an AUC of 0.689 ± 0.046 (p=1.54E-4), and further 
inclusion of the 4 lipid biomarkers increased the AUC to 0.741 ± 0.045 (p=1.33E-6) 
(Fig. 2c). Graphically, the improvement in AUC was most marked at stringent 
thresholds, i.e. enhancing the sensitivity at high levels of specificity. For instance at 
91.7% specificity, sensitivity is 21.6% based on traditional risk factors, but raised to 
48.6% when lipid predictors are included. In addition, there was some improvement 
at high levels of sensitivity, for instance at 97.3% sensitivity, where the inclusion of 
lipid predictors raised specificity from 9.9% based on traditional risk factors alone to 
24.9%. 
Finally, we sought to identify the most parsimonious model from these 6 potential 
predictive variables. Using a backward stepwise selection algorithm, the only terms 
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left in the model were Maternal BMI, TG(48:1) and PCae(40:4). This yielded an AUC 
of 0.732 ± 0.045 (p=3.28E-6), which is similar to the model including all 6 predictors. 
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Conclusions 
In this unselected cohort of predominantly Caucasian pregnant women, using an 
unbiased lipidomics approach and a pre-assigned validation cohort, we show for the 
first time that specific lipid species in the maternal early second trimester lipid profile 
are associated with maternal glycemic traits assessed by standard 75g oral glucose 
tolerance testing at 28 weeks. We identified 4 lipid biomarkers, i.e. TG(51:1), 
TG(48:1), PC(32:1) and PCae(40:4), that predict later GDM independent of maternal 
age and BMI, and could potentially enhance the performance of existing risk-factor 
based screening approaches used in many countries. 
The performance of clinical risk-factor based screening has been examined in many 
different populations. A recent study in an Australian population compared the 
performance of the NICE, ADA and Australasian Diabetes in Pregnancy Society risk-
factor based screening guidelines, yielding sensitivities of 92%, 100% and 99%, and 
specificities of 32.4%, 3.9% and 13.7% respectively (24). This and other studies 
reveal limited test performance, with the need for low levels of specificity to achieve 
the high levels of sensitivity.   
The 4 lipid biomarkers that we identified have moderate predictive performance, with 
an estimated AUC of 0.709. This is comparable to other early pregnancy biomarkers, 
including conventional biomarkers fasting plasma glucose (estimated AUC=0.579) 
(9), HbA1C (AUC in high risk population=0.67) (25), triglycerides (AUC=0.55-0.61) 
and triglycerides to HDL ratio (AUC=0.62) (26), as well as novel biomarkers such as 
second trimester serum miRNA (AUC=0.669) (13). Furthermore the  lipid biomarkers 
that we derived were specifically identified to predict GDM independent of maternal 
age and BMI, and thus can enhance the predictive performance of existing risk 
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factor-based approaches. Indeed, inclusion of the 4 lipid biomarkers to maternal age 
and BMI increased the AUC from 0.689 to 0.741.  
The enhancement of sensitivity at high levels of specificity was particularly marked. 
Although for the purpose of predicting GDM, our data on the clinical performance of 
lipid biomarkers must be considered very preliminary, lipid biomarkers may 
potentially have a role in identifying high-risk women who should receive an 
immediate/early second trimester OGTT.  
The lipid biomarkers we identified can be divided into two groups. TG(51:1), TG(48:1) 
and PC(32:1) are associated with increased post-load glucose levels and GDM risk, 
and are moderately correlated. The choline ether phospholipids PCae(40:3) and 
PCae(40:4) are associated with decreased post-load glucose levels and/or GDM risk, 
and are strongly correlated.  
The association of TG(51:1), TG(48:1) and PC(32:1) with maternal glucose levels is 
consistent with previous investigations into lipidomic changes associated with Type 2 
diabetes. TG(48:1) has been implicated with Type 2 diabetes risk in the Framingham 
cohort (27), and PC(32:1) levels are raised in AusDiab subjects with Type 2 Diabetes 
(28). These 3 lipid species are notable for the presence of a single double bond, 
which implies the presence of a monounsaturated fatty acid (MUFA), predominantly 
palmitoleate and to a lesser extent, oleate, on closer inspection of LC-MS spectra in 
our analysis. In one study, palmitoleate content within circulating phospholipids was 
found to be associated with increased insulin resistance (29). As circulating 
palmitoleate is principally synthesized in the liver in humans, this may reflect hepatic 
insulin resistance, in line with our finding that TG(51:1) is associated with fasting 
plasma glucose levels (30). Mechanistically, palmitoleate and oleate are produced 
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from palmitate and stearate by the action of Steroyl-CoA desaturase 1 (SCD1), and 
SCD1 activity has recently been linked in a large cohort to Type 2 Diabetes risk and 
hepatic steatosis (31). Indeed, SCD1-/- mice display increased insulin sensitivity (32).  
The association of TG(51:1), primarily comprising TG(18:1/17:0/16:0) (or positional 
isomers thereof) in our cohort, with maternal glucose levels was also surprising 
because odd-chain fatty acids, including heptadecanoic acid, have been associated 
with reduced risk of Type 2 Diabetes (28,33,34). However, our finding is in keeping 
with results of an untargeted metabolomic screen using fasted serum samples from 
women at 28 weeks gestation who were enrolled in the HAPO study (35), in which 
heptadecanoic acid was raised in subjects with fasting plasma glucose levels in the 
90th percentile but with similar BMI to controls. This may be due to genuine 
differences in the pathophysiology of GDM and Type 2 Diabetes, but may also reflect 
the fact that the studies of Type 2 Diabetes measured the fatty acid content in 
phospholipids, whereas the latter study of pregnant women measured free fatty 
acids (35). This underscores the advantage of intact lipid studies as opposed to fatty-
acid profiling (30), which is a strength of our study. 
The other group of lipid biomarkers identified, i.e. the choline ether phospholipids 
PCae(40:3) and PCae(40:4), were inversely associated with maternal glucose levels. 
This is consistent with an earlier report from the AusDiab cohort in which ether 
phospholipids  were inversely related with post-load glucose levels and reduced in 
patients with diabetes (28). The physiological function of ether phospholipids 
remains largely unknown (36), but they have been implicated as physiological 
ligands of PPARγ (37). Intriguingly, SCD1 is a target of PPARγ, potentially providing 
a mechanistic link between low ether phospholipids, and high levels of palmitoleate- 
and oleate- containing lipids (32). 
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The broad overlap between our lipid biomarkers and those identified in studies of 
Type 2 Diabetes may be due to the fact that lipid profiles were derived from samples 
obtained early in pregnancy, reflecting the contribution of pre-existing insulin 
resistance to the development of Gestational Diabetes. Indeed, it will be ideal to 
obtain a pre-conceptional sample as well as one during pregnancy, to identify lipid 
biomarkers which reflect the pathophysiological contribution of pregnancy itself. 
Nevertheless, this explanation of our findings is made less likely by the fact that 
GWAS studies have revealed a broadly shared genetic architecture between GDM 
and Type 2 Diabetes, and metabolomic studies from later in pregnancy, including 
one using samples from 28 weeks gestation, have shown overlapping metabolic 
signatures between GDM and Type 2 diabetes (11,14,35). 
There are several limitations to our study. First, while we validated our candidate 
lipid biomarkers using a pre-defined subset, these biomarkers have not been 
externally validated, for example in populations of high-risk ethnicities. Second, our 
study was not designed to demonstrate the superiority of a lipid biomarker and risk-
factor based approach compared to a risk-factor based screening alone. Thus, we 
lacked data on other conventional risk factors, e.g. family history of diabetes and 
personal history of GDM. For similar reasons, we also lacked data on other 
traditional biochemical risk factors, such as HbA1C, triglycerides and HDL cholesterol, 
and are thus unable to directly compare the performance of the lipid biomarkers to 
these alternatives within this study. Third, because we selected only 13 lipids from 
the 189 lipids measured for univariate analysis, we might have been overly 
conservative in our approach. Finally, because serum samples for lipidomic analysis 
were obtained in the non-fasting state without controlling for meal time and meal 
content, this would have added additional lipidomic variability that was not related to 
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variation in OGTT results at 28 weeks, thus reducing study power. However, this 
additional variability might be small compared to existing inter- and intra-subject 
variation (38).  Our re-analysis of data from Begum and colleagues (38) suggests 
that variance is partitioned between inter-subject differences, intra-subject 
differences not due to meal time, and the effect of meal time in the proportion 62%, 
31% and 7%, albeit the population that they studied was less heterogeneous than 
the CBGS. 
In summary, we report for the first time an association between maternal early 
second trimester lipid species and glycemic traits at 28 weeks, as assessed by a 
standard OGTT. We further show that 4 lipid biomarkers, TG(51:1), TG(48:1), 
PC(32:1) and PCae(40:4) are able to predict maternal GDM status independent of 
maternal age and BMI, and have potential to improve the performance of clinical 
risk-factor based screening. The lipid biomarkers identified also revealed marked 
similarities between the pathophysiology of GDM and Type 2 Diabetes (14). In 
particular, we highlight the established role of MUFAs (especially palmitoleate) and 
the emerging role of ether phospholipids, as well as the potential pathological role of 
odd-chain fatty acids, which might indicate a divergence in the pathophysiologies of 
GDM and Type 2 Diabetes. 
  
19 
 
Acknowledgements 
L.L., A.K., C.J.P. and D.B.D. designed the study, interpreted the data and edited the 
manuscript. A.K., B.J. and L.M. collected the data. L.L. analyzed the data and 
drafted the manuscript. I.A.H., C.L.A. and K.K.O. contributed to discussion and 
reviewed the manuscript. L.L and D.B.D. are the guarantors of this work and, as 
such, had full access to all the data in the study and take responsibility for the 
integrity of the data and the accuracy of the data analysis. 
The authors acknowledge the excellent laboratory assistance provided by Dianne 
Wingate, Rachel Seear, Katrin Mooslehner and Radka Platte. The authors would like 
to express their appreciation to the families who participated in this study, and 
acknowledge the important contributions made by the research nurses, including 
Suzanne Smith, Ann-Marie Wardell and Karen Forbes, as well as the assistance 
provided by colleagues at the Addenbrooke's Wellcome Trust Clinical Research 
Facility and midwives at the Rosie Maternity Hospital in data collection. 
This part of the Cambridge Baby Growth Study was funded by grants from the 
Wellbeing of Women (RG1644) and Diabetes UK (11/0004241). The lipidomics 
assays were supported by the Medical Research Council (UD99999906) and 
Cambridge Lipidomics Biomarker Research Initiative (G0800783). Core funding was 
also obtained through the Medical Research Council, European Union Framework 5 
World Cancer Research Fund, Mothercare Foundation and the Newlife Foundation 
for Disabled Children. There has also been support from National Institute for Health 
Research Cambridge Biomedical Research Centre. 
There were no potential conflicts of interests reported. This work has not been 
published elsewhere, either in whole or in part.  
20 
 
Figure legends 
Figure 1. Candidate lipid biomarkers identified from the Discovery Cohort. (a-b) 
Variable Importance in Projection scores of individual lipid species in a PLS model 
mapping early 2nd trimester lipid profiles to late 2nd trimester 1-hour post-load 
glucose levels (b) Variable Importance in Projection Scores of individual lipid species 
in a PLS-DA model mapping early 2nd  trimester lipid profiles to membership in the 
top tertile of late 2nd trimester 1-hour post-load glucose levels (c) Correlation 
between 10 candidate lipid biomarkers taken forward to validation cohort. PCae: 
Choline ether phospholipid; TG: Triglyceride; PE: Phosphatidylethanolamine; PC: 
Phosphatidylcholine. Underlined lipid species refer to species which had nominally 
significant associations with 1-hour post-load glucose levels (a) or the top tertile 
thereof (b), and were taken forward to the Validation cohort. 
Figure 2. Validated lipid biomarkers and Gestational Diabetes prediction within the 
Validation Cohort. (a) Individual predictive power of each lipid, independent of 
maternal age and BMI. * refers to P<0.05, with Benjamini-Hochberg correction for 
multiple testing (b) Combined predictive power of 4 lipid species (c) Enhancement of 
predictive power of conventional risk factors. AUC: Area under the curve. Other 
abbreviations as per Figure 1.  
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Tables 
Clinical Characteristics  All OGTT  Lipidomics Total  Discovery cohort Validation cohort  Discovery VS Validation  
Mean SD Mean SD Mean SD Mean SD p-value 
Total number, n 1069   817    200    617      
Age (Years) 33.39 4.19 33.27 4.11 33.38 3.83 33.22 4.21 0.65  
Maternal pre-pregnancy 
BMI (kg/m
2
) 24.10 4.46 24.19 4.48 23.90 4.13 24.30 4.60 0.31  
Maternal height (m) 1.66  0.07 1.66 0.07 1.66 0.07 1.66 0.07 0.22  
Fasting glucose levels 
(mM) 4.33 0.55 4.33 0.49 4.33 0.53 4.32 0.47 0.93  
1h post-load glucose levels 
(mM) 6.83 1.72 6.77 1.67 6.57 1.59 6.84 1.69 0.05  
Gestational Diabetes (%) 9.45   8.20   6.50   8.75   0.38  
Gestational Age at serum 
sample collection 15.2 2.46 15.0 2.02 14.6 1.73 15.1 2.10 0.004 
 
Table 1. Clinical characteristics of participants in the Lipidomics Study. Fasting and 
post-load glucose levels were measured using a standard oral glucose tolerance test 
at 28 weeks of pregnancy. Gestational diabetes was diagnosed based on fasting and 
1h post-load venous plasma glucose measurements (details in text). Comparisons 
were performed using Student’s t-test and χ2 for the proportion of participants with 
gestational diabetes. P-values were not corrected for multiple testing.  
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Lipid Species  
Univariate Analysis  Adjusted for Maternal age and BMI  
Regression 
coefficient 
(mM per SD)  
p-value BH  p-value  
Regression 
coefficient 
(mM per SD)  
p-value BH  p-value 
TG(51:1)  0.18 9.15E-03 0.02 0.18 0.03 0.05 
TG(48:1)  0.27 1.00E-04 3.82E-04 0.22 7.40E-03 0.02 
TG(50:1)  0.07 0.31 0.40 -0.06 0.45 0.50 
PC(32:1)  0.33 1.45E-06 1.31E-05 0.21 8.94E-03 0.02 
PCae(38:4)  -0.06 0.39 0.44 -0.15 0.06 0.09 
PCae(44:6)  0.02 0.80 0.80 -0.03 0.69 0.69 
PCae(40:3)  -0.26 1.70E-04 3.82E-04 -0.24 3.63E-03 0.02 
PCae(40:5)  -0.16 0.02 0.03 -0.14 0.08 0.10 
PCae(40:4)  -0.27 1.31E-04 3.82E-04 -0.29 2.60E-04 2.34E-03 
 
Table 2. Relationship between candidate lipid biomarkers and 2nd trimester 1-hour 
post-load glucose levels in the Validation Cohort. BH: Benjamini-Hochberg corrected. 
Abbreviations as per Figure 1. P-values in bold type indicate a statistically significant 
result (P<0.05).  
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